Patents by Inventor Dave A. Miller

Dave A. Miller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12023343
    Abstract: Compositions and methods for making a pharmaceutical dosage form include making a pharmaceutical composition that includes one or more active pharmaceutical ingredients (API) with one or more pharmaceutically acceptable excipients by thermokinetic compounding into a composite. Compositions and methods of preprocessing a composite comprising one or more APIs with one or more excipients include thermokinetic compounding, comprising thermokinetic processing the APIs with the excipients into a composite, wherein the composite can be further processed by conventional methods known in the art, such as hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding.
    Type: Grant
    Filed: July 25, 2022
    Date of Patent: July 2, 2024
    Assignees: AustinPx, LLC, Board of Regents, The University of Texas System
    Inventors: Chris Brough, James W. McGinity, Dave A. Miller, James C. Dinunzio, Robert O. Williams, III
  • Publication number: 20240091201
    Abstract: The disclosure provides for improved pharmaceutical compositions containing deferasirox (DFX) and methods of manufacturing the same. In particular, the compositions are prepared using thermokinetic compounding and provide improved properties as well as more efficient methods of manufacture.
    Type: Application
    Filed: November 24, 2023
    Publication date: March 21, 2024
    Applicant: AustinPx, LLC
    Inventors: Dave A. MILLER, Justin M. KEEN, Sandra U. KUCERA
  • Patent number: 11878005
    Abstract: The disclosure provides for improved pharmaceutical compositions containing deferasirox (DFX) and methods of manufacturing the same. In particular, the compositions are prepared using thermokinetic compounding and provide improved properties as well as more efficient methods of manufacture.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: January 23, 2024
    Assignee: AustinPx, LLC
    Inventors: Dave A. Miller, Justin M. Keen, Sandra U. Kucera
  • Publication number: 20230172949
    Abstract: Compositions and methods for making a pharmaceutical dosage form include making a pharmaceutical composition that includes one or more active pharmaceutical ingredients (API) with one or more pharmaceutically acceptable excipients by thermokinetic compounding into a composite. Compositions and methods of preprocessing a composite comprising one or more APIs with one or more excipients include thermokinetic compounding, comprising thermokinetic processing the APIs with the excipients into a composite, wherein the composite can be further processed by conventional methods known in the art, such as hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding.
    Type: Application
    Filed: July 25, 2022
    Publication date: June 8, 2023
    Applicants: BOARD OF REGENTS, THE UNIVERISTY OF TEXAS SYSTEM, AustinPx, LLC
    Inventors: Chris BROUGH, James W. MCGINITY, Dave A. MILLER, James C. DINUNZIO, Robert O. WILLIAMS, III
  • Patent number: 11439650
    Abstract: Compositions and methods for making a pharmaceutical dosage form include making a pharmaceutical composition that includes one or more active pharmaceutical ingredients (API) with one or more pharmaceutically acceptable excipients by thermokinetic compounding into a composite. Compositions and methods of preprocessing a composite comprising one or more APIs with one or more excipients include thermokinetic compounding, comprising thermokinetic processing the APIs with the excipients into a composite, wherein the composite can be further processed by conventional methods known in the art, such as hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding.
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: September 13, 2022
    Assignees: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, DISPERSOL TECHNOLOGIES, LLC
    Inventors: Chris Brough, James W. McGinity, Dave A. Miller, James C. DiNunzio, Robert O. Williams, III
  • Publication number: 20210128536
    Abstract: The present disclosure relates to pharmaceutical formulations including a weakly basic drug and an ionic polymer in an amorphous solid dispersion, as well as methods of forming such pharmaceutical formulations, and methods of administering such pharmaceutical formulations.
    Type: Application
    Filed: October 8, 2020
    Publication date: May 6, 2021
    Applicants: DISPERSOL TECHNOLOGIES, LLC, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Robert O. WILLIAMS, III, Scott V. JERMAIN, Daniel Alan DAVIS, Dave A. MILLER
  • Publication number: 20200261473
    Abstract: Compositions and methods for making a pharmaceutical dosage form include making a pharmaceutical composition that includes one or more active pharmaceutical ingredients (API) with one or more pharmaceutically acceptable excipients by thermokinetic compounding into a composite. Compositions and methods of preprocessing a composite comprising one or more APIs with one or more excipients include thermokinetic compounding, comprising thermokinetic processing the APIs with the excipients into a composite, wherein the composite can he further processed by conventional methods known in the art, such as hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding.
    Type: Application
    Filed: May 5, 2020
    Publication date: August 20, 2020
    Applicants: BOARD OF REGENTS, THE UNIVERISTY OF TEXAS SYSTEM, DISPERSOL TECHNOLOGIES, LLC
    Inventors: Chris BROUGH, James W. MCGINITY, Dave A. MILLER, James C. DINUNZIO, Robert O. WILLIAMS, III
  • Patent number: 10668085
    Abstract: Compositions and methods for making a pharmaceutical dosage form include making a pharmaceutical composition that includes one or more active pharmaceutical ingredients (API) with one or more pharmaceutically acceptable excipients by thermokinetic compounding into a composite. Compositions and methods of preprocessing a composite comprising one or more APIs with one or more excipients include thermokinetic compounding, comprising thermokinetic processing the APIs with the excipients into a composite, wherein the composite can be further processed by conventional methods known in the art, such as hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: June 2, 2020
    Assignees: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, DISPERSOL TECHNOLOGIES, LLC
    Inventors: Chris Brough, James W. McGinity, Dave A. Miller, James C. DiNunzio, Robert O. Williams, III
  • Publication number: 20200009060
    Abstract: The disclosure provides for improved pharmaceutical compositions containing an active pharmaceutical ingredient and a non-polymeric lubricant and methods of manufacturing the same. In particular, the compositions are prepared using thermal processing or solvent sprying and provide improved properties as well as more efficient methods of manufacture.
    Type: Application
    Filed: May 8, 2017
    Publication date: January 9, 2020
    Applicant: DISPERSOL TECHNOLOGIES, LLC
    Inventors: Dave A. MILLER, Daniel J. ELLENBERGER, Sandra U. SCHILLING
  • Publication number: 20190167643
    Abstract: The disclosure provides for improved pharmaceutical compositions containing deferasirox (DFX) and methods of manufacturing the same. In particular, the compositions are prepared using thermokinetic compounding and provide improved properties as well as more efficient methods of manufacture.
    Type: Application
    Filed: February 6, 2019
    Publication date: June 6, 2019
    Applicant: DISPERSOL TECHNOLOGIES, LLC
    Inventors: Dave A. MILLER, Justin M. KEEN, Sandra U. KUCERA
  • Publication number: 20190142756
    Abstract: The disclosure provides for improved pharmaceutical compositions containing an active pharmaceutical ingredient and a non-polymeric lubricant and methods of manufacturing the same. In particular, the compositions are prepared using thermal processing or solvent spraying and provide improved properties as well as more efficient methods of manufacture.
    Type: Application
    Filed: November 9, 2018
    Publication date: May 16, 2019
    Applicant: DISPERSOL TECHNOLOGIES, LLC
    Inventors: Dave A. MILLER, Daniel J. ELLENBERGER, Sandra U. SCHILLING
  • Patent number: 10265301
    Abstract: The disclosure provides for improved pharmaceutical compositions containing deferasirox (DFX) and methods of manufacturing the same. In particular, the compositions are prepared using thermokinetic compounding and provide improved properties as well as more efficient methods of manufacture.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: April 23, 2019
    Assignee: DISPERSOL TECHNOLOGIES, LLC
    Inventors: Dave A. Miller, Justin M. Keen, Sandra U. Kucera
  • Patent number: 10258608
    Abstract: The disclosure provides for improved pharmaceutical compositions containing deferasirox (DFX) and methods of manufacturing the same. In particular, the compositions are prepared using thermokinetic compounding and provide improved properties as well as more efficient methods of manufacture.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: April 16, 2019
    Assignee: DISPERSOL TECHNOLOGIES, LLC
    Inventors: Dave A. Miller, Justin M. Keen, Sandra U. Kucera
  • Publication number: 20180360850
    Abstract: Compositions and methods for making a pharmaceutical dosage form include making a pharmaceutical composition that includes one or more active pharmaceutical ingredients (API) with one or more pharmaceutically acceptable excipients by thermokinetic compounding into a composite. Compositions and methods of preprocessing a composite comprising one or more APIs with one or more excipients include thermokinetic compounding, comprising thermokinetic processing the APIs with the excipients into a composite, wherein the composite can be further processed by conventional methods known in the art, such as hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding.
    Type: Application
    Filed: June 19, 2018
    Publication date: December 20, 2018
    Applicants: BOARD OF REGENTS, THE UNIVERISTY OF TEXAS SYSTEM, DISPERSOL TECHNOLOGIES, LLC
    Inventors: Chris BROUGH, James W. MCGINITY, Dave A. MILLER, James C. DINUNZIO, Robert O. WILLIAMS, III
  • Patent number: 10022385
    Abstract: Compositions and methods for making a pharmaceutical dosage form include making a pharmaceutical composition that includes one or more active pharmaceutical ingredients (API) with one or more pharmaceutically acceptable excipients by thermokinetic compounding into a composite. Compositions and methods of preprocessing a composite comprising one or more APIs with one or more excipients include thermokinetic compounding, comprising thermokinetic processing the APIs with the excipients into a composite, wherein the composite can be further processed by conventional methods known in the art, such as hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: July 17, 2018
    Assignees: Board of Regents, The University of Texas System, DisperSol Technologies, LLC
    Inventors: Chris Brough, James W. McGinity, Dave A. Miller, James C. Dinunzio, Robert O. Williams, III
  • Publication number: 20170296514
    Abstract: The disclosure provides for improved pharmaceutical compositions containing deferasirox (DFX) and methods of manufacturing the same. In particular, the compositions are prepared using thermokinetic compounding and provide improved properties as well as more efficient methods of manufacture.
    Type: Application
    Filed: June 28, 2017
    Publication date: October 19, 2017
    Applicant: DISPERSOL TECHNOLOGIES, LLC
    Inventors: Dave A. MILLER, Justin M. KEEN, Sandra U. KUCERA
  • Patent number: 9730894
    Abstract: A hot-melt extruded composition having finely divided drug-containing particles dispersed within a polymeric and/or lipophyllic carrier matrix is provided. The carrier softens or melts during hot-melt extrusion but it does not dissolve the drug-containing particles during extrusion. As a result, a majority or at least 90% wt. of the drug-containing particles in the extrudate are deaggregated during extrusion into essentially primary crystalline and/or amorphous particles. PEO is a suitable carrier material for drugs insoluble in the solid state in this carrier. Various functional excipients can be included in the carrier system to stabilize the particle size and physical state of the drug substance in either a crystalline and/or amorphous state. The carrier system is comprised of at least one thermal binder, and may also contain various functional excipients, such as: super-disintegrants, antioxidants, surfactants, wetting agents, stabilizing agents, retardants, or similar functional excipients.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: August 15, 2017
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Dave A. Miller, Jason T. McConville, James W. McGinity, Robert O. Williams, III
  • Publication number: 20170119669
    Abstract: A hot-melt extruded composition having finely divided drug-containing particles dispersed within a polymeric and/or lipophyllic carrier matrix is provided. The carrier softens or melts during hot-melt extrusion but it does not dissolve the drug-containing particles during extrusion. As a result, a majority or at least 90% wt. of the drug-containing particles in the extrudate are deaggregated during extrusion into essentially primary crystalline and/or amorphous particles. PEO is a suitable carrier material for drugs insoluble in the solid state in this carrier. Various functional excipients can be included in the carrier system to stabilize the particle size and physical state of the drug substance in either a crystalline and/or amorphous state. The carrier system is comprised of at least one thermal binder, and may also contain various functional excipients, such as: super-disintegrants, antioxidants, surfactants, wetting agents, stabilizing agents, retardants, or similar functional excipients.
    Type: Application
    Filed: November 2, 2016
    Publication date: May 4, 2017
    Inventors: Dave A. MILLER, Jason T. McCONVILLE, James W. McGINITY, Robert O. WILLIAMS, III
  • Publication number: 20170027911
    Abstract: The disclosure provides for improved pharmaceutical compositions containing deferasirox (DFX) and methods of manufacturing the same. In particular, the compositions are prepared using thermokinetic compounding and provide improved properties as well as more efficient methods of manufacture.
    Type: Application
    Filed: June 17, 2016
    Publication date: February 2, 2017
    Applicant: Dispersol Technologies, LLC
    Inventors: Dave A. MILLER, Justin M. KEEN, Sandra U. KUCERA
  • Patent number: 9504658
    Abstract: A hot-melt extruded composition having finely divided drug-containing particles dispersed within a polymeric and/or lipophyllic carrier matrix is provided. The carrier softens or melts during hot-melt extrusion but it does not dissolve the drug-containing particles during extrusion. As a result, a majority or at least 90% wt. of the drug-containing particles in the extrudate are deaggregated during extrusion into essentially primary crystalline and/or amorphous particles. PEO is a suitable carrier material for drugs insoluble in the solid state in this carrier. Various functional excipients can be included in the carrier system to stabilize the particle size and physical state of the drug substance in either a crystalline and/or amorphous state. The carrier system is comprised of at least one thermal binder, and may also contain various functional excipients, such as: super-disintegrants, antioxidants, surfactants, wetting agents, stabilizing agents, retardants, or similar functional excipients.
    Type: Grant
    Filed: November 9, 2005
    Date of Patent: November 29, 2016
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Dave A. Miller, Jason T. McConville, James W. McGinity, Robert O. Williams, III